Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy.

Area of Science:

• Muscle Physiology
• Skeletal Muscle Biology
• Biochemistry

Background:

• Disuse-induced diaphragmatic dysfunction (DIDD) is a critical clinical issue linked to diaphragm paralysis and mechanical ventilation.
• MuRF1, a key E3-ligase, plays a significant role in skeletal muscle mass regulation and contributes to DIDD onset.

Purpose of the Study:

• To investigate the protective effects of MyoMed-205, a small-molecule inhibitor of MuRF1, against early DIDD.
• To determine the optimal dosage and acute toxicity of MyoMed-205 in Wistar rats.

Main Methods:

• Unilateral diaphragm denervation in Wistar rats for 12 hours.
• Evaluation of diaphragm contractile function and fiber cross-sectional area (CSA).
• Western blotting to analyze molecular mechanisms, including oxidative stress markers, HDAC4 phosphorylation, FoxO1 activation, MuRF2, and Akt phosphorylation.

Main Results:

• A dosage of 50 mg/kg bw MyoMed-205 effectively prevented diaphragmatic contractile dysfunction and atrophy post-denervation without acute toxicity.
• MyoMed-205 normalized HDAC4 phosphorylation, mitigated FoxO1 activation, inhibited MuRF2, and increased phospho-Akt levels.
• Treatment did not alter the increase in oxidative stress (4-HNE) associated with disuse.

Conclusions:

• MuRF1 activity is a significant contributor to the pathophysiology of early DIDD.
• MyoMed-205 demonstrates therapeutic potential for treating early stages of DIDD by targeting MuRF1.